Pyxis Oncology Raises $50M in Private Placement, Extends Cash Runway to Q2 2027
PYXS has more than doubled off its 52-week low of $0.97.
Summary
Pyxis Oncology has finalized a private placement, raising $50 million in gross proceeds, with accompanying warrants that could generate an additional $64 million. This financing is critical, as the company reported a "going concern" warning and a cash runway only into Q4 2026 in its Q1 earnings report in May. The proceeds are expected to extend the company's cash runway into Q2 2027 and fund clinical milestones for its MICVO program. The upfront capital significantly alleviates immediate liquidity concerns and provides crucial funding for ongoing operations and development.
At the time of this announcement, PYXS was trading at $2.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.6M. The 52-week trading range was $0.97 to $5.55. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.